Role of PAPP-A in Graves' Ophthalmopathy

PAPP-A 在格雷夫斯眼病中的作用

基本信息

  • 批准号:
    10651452
  • 负责人:
  • 金额:
    $ 7.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-01-18 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Graves’ Ophthalmopathy (GO) is the most serious extra-thyroidal complication that develops in patients with autoimmune Graves’ hyperthyroidism. It is characterized by increased orbital fat volume and extra-ocular muscle within the unyielding bony orbit, which can have deleterious consequences on eye function. Orbital decompression surgery is an effective but invasive treatment used for severe GO. A better understanding of the pathological mechanisms underlying GO may identify novel targets to inhibit the development and progression of GO before any clinical manifestation. Insulin-like growth factor-I receptor (IGF-IR) signaling has been found to be essential in promoting GO pathogenesis. A monoclonal antibody that binds to and blocks IGF-IR signaling, was recently FDA-approved for treatment of GO. However, adverse events have been documented, all likely due to the ubiquitous nature of IGF-IR. A better understanding of IGF signaling and its regulation in orbital tissue is needed to fully understand mechanism and avoid/reduce off-target consequences. One approach would be to target modifiers of IGF-IR signaling, instead of the IGF-IR per se. We propose PAPP-A as such a target. PAPP-A is a novel zinc metalloprotease that can increase pericellular IGF bioavailability through cleavage of inhibitory IGF binding proteins, in particular IGFBP-4. Conversely, inhibition of PAPP-A expression or its proteolytic activity represents an innovative approach to decrease IGF availability with resultant attenuation of IGF-IR signaling. Interestingly, the most potent stimulators of PAPP-A expression are pro-inflammatory cytokines, which are increased in orbital tissue from GO patients. We hypothesize that PAPP-A is a key modulator of IGF-R signaling in GO. Our Specific Aims are to: 1) Determine PAPP-A expression (basal and pro-inflammatory cytokine-induced) in orbital fibroblasts from GO patients and control subjects. 2) Determine the effect of a neutralizing monoclonal antibody that specifically inhibits PAPP-A- mediated IGFBP-4 proteolysis on IGF-I stimulated proliferation and differentiation in orbital fibroblasts from GO patients. We have primary fibroblasts from retro-orbital fat of GO patients at early passage in-hand and the experience with culture and analyses to establish feasibility. Preliminary results support a role for PAPP-A in GO. We anticipate outcomes from the proposed experiments that could ultimately lead to a novel targeted therapy for patients with GO.
项目摘要 Graves眼病(GO)是甲状腺外最严重的并发症, 自身免疫性格雷夫斯甲状腺机能亢进症其特征是眼眶脂肪体积增加和眼外 坚硬的骨性眼眶内的肌肉,这可能对眼睛功能产生有害后果。轨道 减压手术是用于严重GO的有效但侵入性的治疗。更好地了解 GO的病理机制可能会发现新的靶点来抑制GO的发展, 在出现任何临床表现之前,GO进展。 已经发现胰岛素样生长因子-I受体(IGF-IR)信号传导在促进GO中是必需的。 发病机制一种结合并阻断IGF-IR信号传导的单克隆抗体最近被FDA批准 治疗GO。然而,已经记录了不良事件,所有这些都可能是由于 IGF-IR:需要更好地了解IGF信号传导及其在眼眶组织中的调节,以充分理解 机制,避免/减少脱靶后果。一种方法是靶向IGF-IR的修饰剂 信号,而不是IGF-IR本身。我们建议把《行动纲领》A作为这样一个目标。 PAPP-A是一种新型的锌金属蛋白酶,可以通过切割 抑制性IGF结合蛋白,特别是IGFBP-4。相反,抑制PAPP-A表达或其 蛋白水解活性代表了降低IGF可用性的创新方法, IGF-IR信号传导。有趣的是,PAPP-A表达的最有效的刺激物是促炎性的。 细胞因子,其在来自GO患者的眼眶组织中增加。 我们假设PAPP-A是GO中IGF-R信号传导的关键调节剂。我们的具体目标是: 1)确定眼眶中的PAPP-A表达(基础和促炎性尼古丁诱导) 来自GO患者和对照受试者的成纤维细胞。 2)确定特异性抑制PAPP-A-的中和单克隆抗体的作用。 IGFBP-4介导的蛋白水解对IGF-I刺激的眼眶细胞增殖和分化的影响 来自GO患者的成纤维细胞。 我们有来自GO患者眶后脂肪的原代成纤维细胞, 通过培养和分析来确定可行性。初步结果支持PAPP-A在GO中的作用。我们 预期拟议实验的结果,最终可能导致一种新的靶向治疗, 患者GO

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cheryl A. Conover其他文献

Pregnancy-Associated Plasma Protein-A Elevation in Patients With Acute Coronary Syndrome and Subsequent <em>Atorvastatin</em> Therapy
  • DOI:
    10.1016/j.amjcard.2007.07.045
  • 发表时间:
    2008-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Michael D. Miedema;Cheryl A. Conover;Holly MacDonald;Sean C. Harrington;Dedra Oberg;Daniel Wilson;Timothy D. Henry;Robert S. Schwartz
  • 通讯作者:
    Robert S. Schwartz
Transforming growth factor-b 1 modulates insulin-like growth factor binding protein-4 expression and proteolysis in cultured periosteal explants
转化生长因子-b 1 调节培养的骨膜外植体中胰岛素样生长因子结合蛋白-4 的表达和蛋白水解
  • DOI:
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Carlos González;Kiem G. Auw Yang;Joseph H. Schwab;J. Fitzsimmons;M. Reinholz;Zachary T. Resch;L. Bale;Victoria R. Clemens;Cheryl A. Conover;Shawn W. O'Driscoll;G. G. Reinholz
  • 通讯作者:
    G. G. Reinholz
Genetic and Pharmacological Inhibition of PAPP-A Reduces Bleomycin-Induced Pulmonary Fibrosis in Aged Mice via Reduced IGF Signaling
PAPP-A 的遗传和药理学抑制通过减少 IGF 信号传导减少老年小鼠博莱霉素诱导的肺纤维化
  • DOI:
    10.59368/agingbio.20240023
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Cheryl A. Conover;L. Bale;Sally A. West;Claus Oxvig;Kristian S. Andersen;A. Roden;A. Haak
  • 通讯作者:
    A. Haak
Pregnancy associated plasma protein-A is preferentially expressed in plaque of patients with restenosis
  • DOI:
    10.1016/s0735-1097(02)80083-3
  • 发表时间:
    2002-03-06
  • 期刊:
  • 影响因子:
  • 作者:
    Ali E. Denktas;Kristen Shogren;David R. Holmes;Antoni Bayes-Genis;Claus Oxvig;Michael T. Overgaard;Michael Christiansen;Cheryl A. Conover;Robert S. Schwartz
  • 通讯作者:
    Robert S. Schwartz
Hodgkin’s Lymphoma Manifesting with Hypoglycemia
  • DOI:
    10.4158/ep.9.1.96
  • 发表时间:
    2003-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Cacia V. Soares-Welch;Steven R. Zeldenrust;Cheryl A. Conover;Clive S. Grant;F. John Service
  • 通讯作者:
    F. John Service

Cheryl A. Conover的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cheryl A. Conover', 18)}}的其他基金

PAPP-A as a Potential Target in Alzheimer's Disease
PAPP-A 作为阿尔茨海默病的潜在靶点
  • 批准号:
    10577483
  • 财政年份:
    2022
  • 资助金额:
    $ 7.95万
  • 项目类别:
Role of PAPP-A in Pulmonary Fibrosis
PAPP-A 在肺纤维化中的作用
  • 批准号:
    10261323
  • 财政年份:
    2020
  • 资助金额:
    $ 7.95万
  • 项目类别:
Postdoctoral Training Program for Research on Aging
老龄化研究博士后培养项目
  • 批准号:
    9406898
  • 财政年份:
    2016
  • 资助金额:
    $ 7.95万
  • 项目类别:
Postdoctoral Training Program for Research on Aging
老龄化研究博士后培养项目
  • 批准号:
    9272791
  • 财政年份:
    2016
  • 资助金额:
    $ 7.95万
  • 项目类别:
Role of PAPP-A in Atherosclerosis
PAPP-A 在动脉粥样硬化中的作用
  • 批准号:
    8220837
  • 财政年份:
    2009
  • 资助金额:
    $ 7.95万
  • 项目类别:
Role of PAPP-A in Atherosclerosis
PAPP-A 在动脉粥样硬化中的作用
  • 批准号:
    7808809
  • 财政年份:
    2009
  • 资助金额:
    $ 7.95万
  • 项目类别:
Role of PAPP-A in Atherosclerosis
PAPP-A 在动脉粥样硬化中的作用
  • 批准号:
    7637227
  • 财政年份:
    2009
  • 资助金额:
    $ 7.95万
  • 项目类别:
Role of PAPP-A in Atherosclerosis
PAPP-A 在动脉粥样硬化中的作用
  • 批准号:
    8051556
  • 财政年份:
    2009
  • 资助金额:
    $ 7.95万
  • 项目类别:
Dissection of the IGF-Longevity Connection in a Novel Mouse Model
新型小鼠模型中 IGF-长寿连接的剖析
  • 批准号:
    7798008
  • 财政年份:
    2007
  • 资助金额:
    $ 7.95万
  • 项目类别:
Dissection of the IGF-Longevity Connection in a Novel Mouse Model
新型小鼠模型中 IGF-长寿连接的剖析
  • 批准号:
    7193021
  • 财政年份:
    2007
  • 资助金额:
    $ 7.95万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Study of Neuropilin-1 as a potential marker of self-reactive Th cells in autoimmune neuroinflammation
Neuropilin-1 作为自身免疫性神经炎症中自身反应性 Th 细胞潜在标志物的研究
  • 批准号:
    24K10278
  • 财政年份:
    2024
  • 资助金额:
    $ 7.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Shared and distinct genetic architecture of autoimmune and hormonal alopecias
自身免疫性脱发和激素性脱发的共同和独特的遗传结构
  • 批准号:
    MR/X030466/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.95万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
    Operating Grants
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
    Operating Grants
Environmental factors and risk of autoimmune rheumatic disease incidence and serology
环境因素和自身免疫性风湿病发病率和血清学的风险
  • 批准号:
    498306
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
    Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
PTSD and Autoimmune Disease: Towards Causal Effects, Risk Factors, and Mitigators
创伤后应激障碍 (PTSD) 和自身免疫性疾病:因果效应、危险因素和缓解措施
  • 批准号:
    10696671
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease
构建引领 — 建立合作伙伴关系,将暴露组与自身免疫性疾病联系起来
  • 批准号:
    10871040
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
Functional consequences of intergenic autoimmune disease risk variants
基因间自身免疫性疾病风险变异的功能后果
  • 批准号:
    10655161
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 7.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了